Whole body vibration to preserve physical capacity during allogeneic haematopoietic cell transplantatio

Not Applicable

• Conditions: all patients during allogenic stemcelltransplantation; C81-C96; D46; Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue; Myelodysplastic syndromes

• Registration Number: DRKS00009918
• Lead Sponsor: niversitätsklinik Freiburg, Klinik für Innere Medizin I

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03-03
• Study Completion: 2018-02-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

All patients eligible for alloHCT.
All patients able to perform cardiopulmonary exercise test.
Signed informed consent.

Exclusion Criteria

Instable bone metastases,
epilepsy,
endoprothesis in knee or hip,
severe heart disease NYHA III-IV,
pacemaker

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
phyiscal performance (VO2peak) at the time of discharge (T1)

Secondary Outcome Measures

Name	Time	Method
- Physical performance (VO2peak) measured during cardiopulmonary exercise test on cycle ergometer 180 days after alloHCT<br>- mobility und strength [cm;s;F] force platform (Leonardo Mechanograph®)<br>-Maximum strength: maximum voluntary contraction (MVC) of knee extension and flexion (Contrex®)<br>- gait speed and gait variability (Moticon, openGo®)<br>- Thickness of the quadriceps femoris muscle[cm]Ultrasonography at midpoint of the thigh <br>-Body composition (fat-free mass, body cell mass, phase angle) [(°; %)]<br>- qualitiy of life and fatigue (EORTC QLQ C30; EORTC-QLQ_HDC29; MFI) <br>-physical activity before and after diagnosis <br>- FES-I questionnaire<br>-Transplant-specific outcomes<br><br>